

KEREOOS

TARGETED THERAPEUTICS AND MOLECULAR IMAGING



*Institute of Biological Engineering
Annual Meeting*

March 30, 2007

Kereos

- Targeted Imaging / Targeted Therapy

- Cancer

- KI-0001 –Angiogenesis-targeted MRI agent
 - KI-1001 – Targeted tumor therapeutic

- Cardiovascular Disease

- KI-0002 – CV MRI agent under development by BMS
 - KI-1003 – unstable plaque therapy

- Growing pipeline

- Development-focused team

- CMC, pharmacology and clinical

- Strong investor support

- Raised over \$20M in funding to date


Partnerships

- Washington University
 - Broad license and collaboration
 - + Including CV applications
 - Share strong support of NCI and NHLBI
 - + NCI Cancer Center of Nanotechnology Excellence
- Bristol-Myers Squibb Medical Imaging
- Philips Medical Systems
- Dow Chemical

Ligand-Targeted Emulsions

Imaging


- Targeted
- Potent payloads
100 ligands : $\approx 100,000$ payload molecules
- Safe
Stable
Easy to manufacture



Ligand-Targeted Emulsions



Therapy

- Targeted
- Potent payloads
100 ligands : $\approx 100,000$ payload molecules
- Safe
Stable
Easy to manufacture




KI-0001

targeted tumor
MRI agent



KI-0001 tumor-targeted MRI agent




Targets angiogenesis via $\alpha_v\beta_3$ biomarker:

- **Solid tumors**
 - Correlated to tumor aggressiveness, metastasis and patient survival
- **Atherosclerosis**
 - Linked to growing, vulnerable and unstable plaques
- **RA, AMD, etc.**

Angiogenesis-targeted MRI (KI-0001)

MRI of angiogenesis
Find tumors earlier



Angiogenesis-targeted MRI (KI-0001)

MRI of angiogenesis

Find tumors earlier

Assess disease




Angiogenesis-targeted MRI (KI-0001)

MRI of angiogenesis


Find tumors earlier

Assess tumor

Monitor tx response



U.S. Cancer Statistics



Cancer Site	Total Estimated New Cases	Prevalence*	Estimated Deaths	Lifetime Risk of Developing Cancer Male / Female
Colorectal	153,760	1,068,198	52,180	1 in 17 / 1 in 18
Pancreatic	37,170	27,688	33,370	1 in 78 / 1 in 79
Melanoma	59,940	662,433	8,110	1 in 49 / 1 in 73
Breast	180,510	2,369,036	40,910	---- / 1 in 8
Ovarian	22,430	171,840	15,280	---- / 1 in 69



Sources: American Cancer Society, Inc.,
Cancer Facts & Figures 2007; *National
 Cancer Institute's SEER 1975-2003
 (available as of 3/07)

IBE
 March 30, 2007

KEREOs
 TARGETED THERAPEUTICS AND MOLECULAR IMAGING

KI-0001


tumor-targeted
MRI agent



KI-0001 targeted tumor MRI agent

Mid-tumor
Slices at 3T
(3/3 rabbits)

No Baseline
Contrast




Neovascular
Contrast
Enhancement
(w/o baseline
subtraction)

Rabbit VX-2 tumors

KI-0001

targeted tumor
MRI agent



3D
Tumor
Reconstruction
at 3T



IBE
March 30, 2007

KEREOS
TARGETED THERAPEUTICS AND MOLECULAR IMAGING

KI-0001 angiogenesis-targeted MRI agent



fat-fed rabbit aorta (diaphragm)

Product Pipeline

KI-0001	•Targeted tumor MRI•
KI-1001	•Angiogenesis•
KI-0002 <i>BMS</i>	•Targeted CV MRI•
KI-1003	•Unstable plaque•
KI-1004	•Restenosis•




IBE
March 30, 2007



KEREOS
TARGETED THERAPEUTICS AND MOLECULAR IMAGING

KI-1004

targeted
anti-restenotic



KI-1004 targeted anti-restenotic



Balloon overstretch injury in rabbits

Kereos...

- Targeted cancer imaging & therapy
 - 1st product to clinic in 2H07
 - Developing follow-ons to lead MRI agent
- Cardiovascular
 - CV imaging agents
 - CV therapeutics
- Accomplished team
- Partnerships with market leaders

For more information

info@kereos.com

